Huge Potential Market for ASEP Asep Medical is a recently IPOd biotech company on the CSE. They’re focusing mainly on treating sepsis and the antibiotic-resistant market.
Sepsis is a deadly disease that affects 49M people per year and causes 11M deaths out of those 49M. So, they have a sizeable potential market since there are currently no approved drugs for biofilms on the market, with 65% of the sepsis infections coming from biofilms.
$ASEP has two main approaches for treating Sepsis and related diseases.
- Diagnostics: They developed a new diagnostics assay to confirm sepsis using the immune response instead of looking for a specific pathogen. This makes the testing far more sensitive and efficient, taking only 1 hour to get results and begin treatment instead of the usual 24 hours.
- Therapeutics: $ASEP also developed a peptide technology that addresses the ineffectiveness of current treatments by suppressing biofilm regrowth and reducing inflammation Plus, it has potent activity against all clinically relevant antibiotic-resistant biofilms.
With the two main technologies, things are looking promising for the company already. Commercialization is expected to hit in the middle of next year, and we should see significant interest in their technologies. $ASEP isn't just bringing a new drug to the market, they're saving lives. Additionally, they have an experienced management team and around $15M awarded through non-dilutive research grants.
Overall, it's definitely worth it to keep an eye on these guys. Their work will help bring the medical industry to the next level through the novel approaches and technology they're bringing to the market. The stock has been holding out at around $0.50 with support levels in the mid $0.40 range. With the downward momentum finally slowing, it's looking like a pretty attractive entry point with a $28M market cap.